"Fluoxetine" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
The first highly specific serotonin uptake inhibitor. It is used as an antidepressant and often has a more acceptable side-effects profile than traditional antidepressants.
| Descriptor ID |
D005473
|
| MeSH Number(s) |
D02.092.831.280
|
| Concept/Terms |
Fluoxetine- Fluoxetine
- Fluoxetin
- N-Methyl-gamma-(4-(trifluoromethyl)phenoxy)benzenepropanamine
|
Below are MeSH descriptors whose meaning is more general than "Fluoxetine".
Below are MeSH descriptors whose meaning is more specific than "Fluoxetine".
This graph shows the total number of publications written about "Fluoxetine" by people in this website by year, and whether "Fluoxetine" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2002 | 1 | 1 | 2 |
| 2006 | 2 | 0 | 2 |
| 2007 | 0 | 1 | 1 |
| 2008 | 0 | 1 | 1 |
| 2009 | 1 | 0 | 1 |
| 2010 | 0 | 1 | 1 |
| 2021 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Fluoxetine" by people in Profiles.
-
Callaghan K, Rappaport DI. False-Positive Urine Drug Screen for Benzodiazepines in a Child Taking Fluoxetine. Pediatr Emerg Care. 2021 05 01; 37(5):e283.
-
Childers WE, Havran LM, Asselin M, Bicksler JJ, Chong DC, Grosu GT, Shen Z, Abou-Gharbia MA, Bach AC, Harrison BL, Kagan N, Kleintop T, Magolda R, Marathias V, Robichaud AJ, Sabb AL, Zhang MY, Andree TH, Aschmies SH, Beyer C, Comery TA, Day M, Grauer SM, Hughes ZA, Rosenzweig-Lipson S, Platt B, Pulicicchio C, Smith DE, Sukoff-Rizzo SJ, Sullivan KM, Adedoyin A, Huselton C, Hirst WD. The synthesis and biological evaluation of quinolyl-piperazinyl piperidines as potent serotonin 5-HT1A antagonists. J Med Chem. 2010 May 27; 53(10):4066-84.
-
Phillips KA, Kelly MM. Suicidality in a placebo-controlled fluoxetine study of body dysmorphic disorder. Int Clin Psychopharmacol. 2009 Jan; 24(1):26-8.
-
Leonard SK, Dwyer JM, Sukoff Rizzo SJ, Platt B, Logue SF, Neal SJ, Malberg JE, Beyer CE, Schechter LE, Rosenzweig-Lipson S, Ring RH. Pharmacology of neuropeptide S in mice: therapeutic relevance to anxiety disorders. Psychopharmacology (Berl). 2008 May; 197(4):601-11.
-
Beyer CE, Cremers TI. Do selective serotonin reuptake inhibitors acutely increase frontal cortex levels of serotonin? Eur J Pharmacol. 2008 Feb 12; 580(3):350-4.
-
Breza TS, Zheng P, Porcu P, Magro CM. Cutaneous marginal zone B-cell lymphoma in the setting of fluoxetine therapy: a hypothesis regarding pathogenesis based on in vitro suppression of T-cell-proliferative response. J Cutan Pathol. 2006 Jul; 33(7):522-8.
-
Beyer CE, Lin Q, Rosenzweig-Lipson S, Schechter LE. Alpha 2A-adrenoceptors enhance the serotonergic effects of fluoxetine. Eur J Pharmacol. 2006 Jun 13; 539(3):164-7.
-
Beyer CE, Boikess S, Luo B, Dawson LA. Comparison of the effects of antidepressants on norepinephrine and serotonin concentrations in the rat frontal cortex: an in-vivo microdialysis study. J Psychopharmacol. 2002 Dec; 16(4):297-304.
-
Bustillo JR, Lauriello J, Parker K, Hammond R, Rowland L, Bogenschutz M, Keith S. Treatment of weight gain with fluoxetine in olanzapine-treated schizophrenic outpatients. Neuropsychopharmacology. 2003 Mar; 28(3):527-9.